Tudor Investment Corp
RNAM

Tudor Investment Corp’s Avidity Biosciences RNAM Stock Holding History

Tudor Investment Corp’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-733,010
Closed -$52.9M – 4182
2025
Q4 		$52.9M Buy
+733,010
New +$47.3M 0.1% 153
2024
Q3 		– Sell
-66,544
Closed -$2.72M – 3041
2024
Q2 		$2.72M Sell
66,544
-2,343
-3% -$67.2K 0.01% 907
2024
Q1 		$1.76M Buy
+68,887
New +$1.08M 0.01% 1083
2023
Q4 		– Sell
-35,233
Closed -$225K – 2823
2023
Q3 		$225K Buy
35,233
+20,273
+136% +$175K ﹤0.01% 2041
2023
Q2 		$166K Sell
14,960
-2,183
-13% -$27.4K ﹤0.01% 2256
2023
Q1 		$263K Buy
17,143
+4,367
+34% +$96.1K ﹤0.01% 2024
2022
Q4 		$283K Sell
12,776
-6,957
-35% -$104K 0.01% 1943
2022
Q3 		$322K Sell
19,733
-4,226
-18% -$80.8K 0.01% 1743
2022
Q2 		$348K Buy
+23,959
New +$356K 0.01% 1481

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Tudor Investment Corp's RNAM Position: Q1 2026 in Review

Tudor Investment Corp sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 733,010 shares — an estimated $52.9M sold.

Tudor Investment Corp first reported a position in RNAM in Q2 2022 and held it in 9 quarters. The position peaked at $52.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Tudor Investment Corp reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 733,010 Avidity Biosciences shares in Q1 2026, an estimated $52.9M.
  • Tudor Investment Corp first reported a position in Avidity Biosciences in Q2 2022 and held it in 9 quarters.
  • Tudor Investment Corp's Avidity Biosciences position peaked at $52.9M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.